



IPMPC

International Pharmaceutical &
Medical Device Privacy Consortium

2025
YEAR IN
REVIEW

Contents

Letter from IPMPC Chair & Vice Chair	1
Mission	2
Privileges of Membership	3
2025 By the Numbers	4
Insights from Our Members	5-6
Regional Subgroups	7-8
Topical Subgroups	9
IPMPC Privacy and AI Legislative Affiliate (PAILA)	10
IPMPC Cybersecurity Program Team (CPT)	11
2025 New Resources	12
Engagement & Events	13
Member Companies	14
Board of Directors	15
IPMPC Secretariat	16

Letter from the IPMPC Chair



Charlie Blanchard

*Associate Vice President, Global Privacy & Digital Ethics
Amgen*

Dear IPMPC Members and Community,

2025 was another year of profound transformation for privacy professionals in the life sciences industry. Legal, compliance, and privacy operations colleagues faced a new wave of global data laws, the expansion of AI use cases and governance challenges, and geopolitical and economic shifts impacting cross-border data flows. IPMPC continues to serve as the central forum for industry collaboration, thought leadership, and practical guidance on these critical issues -- equipping members with the tools they need to protect individual privacy rights, advance innovation, and enable life-saving healthcare solutions for patients across the globe.

IPMPC now sustains five regional workstreams, reaching every continent in which our member companies operate. This year, the consortium generated practical resources and benchmarking to navigate developments ranging from the U.S. Department of Justice's Data Security Program regulating foreign access to sensitive information, to the EU's digital omnibus legislation amending the GDPR and EU AI Act, to landmark guidance from authorities across the Asia-Pacific, Latin America, the Middle East and Africa.

We continued to tackle data compliance challenges unique to the pharmaceutical and medical device industry through topic-focused initiatives and pop-up roundtable discussions. Priority issues included patient support models and managing the use of generative AI agents. A new workstream, the HR-AI Roundtable, was established to bring together human resources and employment professionals to develop best practices for handling novel AI tools.

The 2025 Year in Review provides IPMPC members and those interested in membership with a snapshot of the consortium's activities, priorities, and deliverables. I am proud to share all we achieved this year through the generous collaboration of our members, and I look forward to working with you in 2026!

A handwritten signature in black ink, appearing to read "C. Blanchard".

Letter from the IPMPC Vice Chair



Laura Donahue

*Associate Vice President, Assistant General Counsel, Digital
Legal Office GRC Program Services and Operations
Eli Lilly and Company*

Dear all,

IPMPC continues to strengthen its collaborations with global stakeholders including EFPIA, MedTech Europe, and BIO -- partnerships that are increasingly important as digital policy developments require the industry to speak with a united voice on issues that directly impact patient outcomes. This year, members gathered in-person in Brussels and Washington, D.C. for live benchmarking, networking, and Q&A discussions with data protection authorities.

As global data laws and regulations adapt to a changing world, so does IPMPC. In this report, you will learn more about the consortium's evolving initiatives and new workstreams. 2025 was the inaugural year of the IPMPC Privacy and AI Legislative Affiliate, through which privacy and government affairs leaders developed resources to support members' advocacy efforts and drive industry alignment on policy priorities. In 2026, we are excited to kick off the Cybersecurity Program Team, hold regular meetings of the China Privacy Compliance Roundtable in Shanghai, and expand benchmarking opportunities at the Board of Directors level.

I invite you to [follow IPMPC on LinkedIn](https://www.linkedin.com/company/ipmpc) or reach out via the IPMPC website to get involved (<https://ipmpc.org>). We are grateful for the support of our members and community!

A handwritten signature in black ink, appearing to read "Laura Donahue".

Our Mission



Provide a forum to ensure that the global life sciences industry speaks with one, coherent voice on data privacy issues



Advance the protection of individual privacy



Augment member companies' data protection capabilities through the development and sharing of industry best practices



Anticipate and respond to new challenges affecting the protection of health information



Educate internal and external stakeholders on data protection in the industry and the importance of data innovation

Privileges of Membership

Timely analyses of new privacy laws, court decisions, and pharmaceutical and medical device enforcement actions impacting business operations

Updates on global privacy developments and informative, practical discussions with local counsel from around the world

Access to extensive privacy-compliance resources tailored to the needs of the pharmaceutical and medical device industry

Cost-sharing to efficiently leverage budget resources

Opportunities to interact with key regulators

Regular interaction and benchmarking with industry colleagues facing similar challenges

Expert insight into how evolving business models could be impacted by privacy laws

Legal, project management, and logistical support by the IPMPC Secretariat

2025 By the Numbers


49 
member companies

50+ 
virtual meetings on key developments in global data laws and regulations and industry benchmarking

500+ 
legal and compliance professionals navigating the privacy, cybersecurity & AI landscape

30+ 
unique topics addressed by aggregated benchmarking surveys

2 
new initiatives launched: IPMPC Cybersecurity Program Team and IPMPC HR-AI Roundtable

40+ 
templates, summaries, and additional resources developed or updated

7 
submitted responses on proposed standards, legislation, & rulemakings

5 pop-up Board of Directors benchmarking teleconferences on top challenges for leaders of global privacy programs

2 in-person IPMPC Board of Directors meetings

2 IPMPC networking receptions held for members and friends in conjunction with industry conferences

1 life sciences privacy bootcamp for members new to the industry or to privacy law

Member Insights



"IPMPC has been an invaluable resource for practical insight and benchmarking on evolving privacy and data protection issues in the MedTech space. The combination of timely analysis of regulatory developments and high quality resources tailored to our industry has helped our Global Privacy team stay informed and offer practical solutions on a variety of topics."



Ericka Snyder
Chief Privacy Counsel
Boston Scientific



"IPMPC continues to be an invaluable resource for Baxter in navigating the rapidly evolving landscape of privacy, AI, and cybersecurity. The working groups consistently provide fecund forums for the discussion of common challenges facing life sciences companies, paired with timely regulatory and enforcement trends that are directly relevant to in-house teams such as ours. Equally important, IPMPC offers credible industry benchmarking that helps us validate and refine our internal processes and policies. The consortium's focus on these somewhat industry-specific issues make it a uniquely useful resource."



James Vinocur
Associate VP, Digital Trust & Risk Legal Lead - Privacy, Cybersecurity & AI
Baxter



"The IPMPC provides detailed insight into a variety of emerging issues in the privacy and AI space – thereby making our membership an invaluable tool for Edwards Lifesciences. Utilizing the knowledge provided by the IPMPC allows our global privacy team to keep pace in a challenging, accelerating environment. Our IPMPC membership provides not only excellent information, but also access to our peers for ongoing benchmarking and professional development."



Jeffrey Dennis
VP, Chief Privacy Officer
Edwards Lifesciences

Member Insights

“The IPMPC is a premier consortium that pairs high-quality resources with a forum for truly collaborative leadership. The ability to engage openly with peers on industry-defining topics facilitates a collegial environment essential for maturing the Privacy Office amidst the rapid evolution of AI. The IPMPC has been instrumental in allowing me to bring diverse, expert perspectives into Sanofi, directly informing our strategic approach to strengthening privacy in Digital & AI.”



Kevin Lewis Kim
Global Privacy Officer, Digital
Sanofi

“Serving as a board member of the IPMPC has been an incredibly valuable experience. The opportunity to engage with peers across the life science industry who are navigating similar challenges and to collaborate on practical solutions together is truly unique. The collective knowledge, shared resources, and meaningful professional connections make participation exceptionally worthwhile. Beyond the insights gained, being part of the IPMPC fosters a strong sense of community and provides a forum to stay ahead of emerging laws, issues and best practices in privacy law and compliance. I highly recommend involvement to anyone looking to grow their expertise and expand their professional network.”



Solace Awumee
Director, Privacy Counsel
Servier

“IPMPC has been an invaluable resource for privacy professionals navigating the diverse and rapidly evolving regulatory landscape across the Asia Pacific region. The consortium provides timely insights into the latest regulatory developments and offers a unique window into how peer companies are approaching the same challenges. The networks and relationships built through IPMPC form a genuine foundation for fulfilling our responsibilities as pharmaceutical companies in this increasingly complex environment.”



Megumi Sugiura
Sr. Director, Digital Legal Office (Japan / NAPAC)
Eli Lilly

European Working Group




- Monitored and reported on key developments including the EDPB v SRB case and evolving approaches to anonymisation and pseudonymisation, the EU Data Act, the European Health Data Space, and proposed digital reform legislation impacting the GDPR and EU AI Act
- Held teleconferences every 6 weeks to receive updates on recent developments and benchmark on priority topics such as secondary use of clinical data, navigating Data Subject Access Requests, and implementing compliance with new laws and regulations
- Organized meeting of EFPIA, MedTech Europe and IPMPC members in Brussels to align on approaches to the European legislative landscape and hear from former CJEU judge Nils Wahl regarding the impact of CJEU rulings on the life sciences industry
- Submitted comments on the EDPB's January 2025 Pseudonymisation Guidelines

CHAIR

Felix Czwikla
GlaxoSmithKline

US Working Group



- Monitored and reported on priority developments including the DOJ Data Security Program (DSP), state-level and FTC enforcement activity, and state and federal privacy, AI, and genetic security legislation
- Held teleconferences every 6 weeks to receive updates on recent developments and benchmark on topics such as DSP implementation and California's regulations on cybersecurity audits, risk assessments, and automated decision-making technology
- Held weekly meetings of the U.S. Strategic Initiatives Subteam to track state and federal legislative activity
- Submitted comments on:
 - CPPA's proposed regulations on cybersecurity audits, risk assessments, automated decision-making technology, and other updates
 - HHS's proposed rule amending the HIPAA security rule
 - House Committee on Energy and Commerce Privacy Working Group's request for information to explore a data privacy and security framework
 - New Jersey's Data Privacy Act proposed rules
 - DOJ's request for information on state law deregulation

CO-CHAIRS

Joanna Levin
Pfizer

Catherine Williams
Genmab

Asia-Pacific Roundtable



- Hosted local counsel for presentations and Q&A on privacy law in key jurisdictions, including Australia, India, South Korea, Malaysia, and China
- Monitored and benchmarked on compliance with new laws and regulations including India's Digital Personal Data Protection Act, South Korea's AI Basic Act, Vietnam's Personal Data Protection Law, and the US DOJ Data Security Program
- Submitted comments on the India Digital Personal Data Protection Act Draft Rules

CHAIR

Viola Pan
Organon

VICE-CHAIR

Lei Fang
Pfizer

Latin America & Canada Roundtable



- Hosted local counsel for presentations and Q&A on privacy law in key jurisdictions, including Brazil, Mexico, Ecuador, and Canada
- Monitored and benchmarked on compliance with new developments including Brazil's data transfer requirements, Mexico's privacy law reform, and AI regulatory trends across the region

CO-CHAIRS

Andrea Walker-Modu
Bristol Myers Squibb

Guilherme Peretti
Organon

Middle East & Africa Roundtable

After standing up the Middle East & Africa Roundtable in 2024, the IPMPC continued to provide updates and analyses on privacy law developments in the region through quarterly "snapshots" of the global privacy law landscape and an overview chart comparing requirements under privacy laws around the world. In 2026, the Middle East & Africa Roundtable will meet quarterly for industry benchmarking and country presentations from local counsel.





Artificial Intelligence (AI) Working Group

- Monitored and reported on key developments including the EU AI Act, the Colorado AI Act, CCPA regulations on automated decisionmaking technology, FDA and EMA guidance on AI use, and the US Executive Order Ensuring a National Policy Framework for Artificial Intelligence
- Held teleconferences every 8 weeks to receive updates on recent developments and benchmark on approaches to AI governance and use cases

CO-CHAIRS

Katherine Lewis
Regeneron

Lionel de Souza
Sanofi



HR-AI Roundtable

In 2025, IPMPC members recognized the need for a forum for HR and employment colleagues in the life sciences industry to benchmark, receive guidance, and share best practices around AI issues in the HR space.

The Roundtable held its first meeting in November 2025, and in 2026 will meet quarterly to discuss priority topics including:

- Governance of AI Tools for HR Purposes
- HR Use Cases of AI Tools
- Works Council Consultations
- AI Literacy and Responsible Use



IPMPC Medical Device Roundtable

Held quarterly benchmarking meetings with MedTech Europe's Data Protection Committee to discuss approaches to key laws and developments such as the EU Data Act and the EU AI Act



IPMPC Privacy Stewardship & Privacy Champion Programs Project Team

Met twice in 2025 to share best practices for operationalizing privacy stewardship and liaison programs and crowdsource ideas for recognizing Data Privacy Day



PAILA

IPMPC Privacy &
AI Legislative Affiliate

IPMPC Privacy and AI Legislative Affiliate (PAILA)

Over the past several years, there has been a flood of U.S. state privacy legislation, and states show a growing interest in the regulation of AI. Absent federal legislation, states continue to pass their own unique privacy and AI legislation. As states pass new laws, it becomes more difficult for life sciences companies to operate consistent privacy programs across the U.S. The IPMPC Privacy and AI Legislative Affiliate (PAILA) was formed by IPMPC members who recognized the need for life sciences companies to engage on privacy and AI legislation.

PAILA kicked off in 2025 to support members' efforts in shaping new privacy and AI policy. PAILA brings together AI and privacy subject matter experts and government affairs and policy colleagues to form a common set of industry principles and positions on privacy and AI legislation and to develop tools and resources to support the members as they advocate based on these principles.

In its inaugural year, PAILA:

- Intensely monitored state and federal privacy and AI legislative activity
- Educated participants and other industry stakeholders on legislative developments and trends
- Facilitated industry alignment on key privacy and AI principles to guide policy priorities
- Created ready-to-use templates to support members' advocacy efforts

"PAILA has been an important and highly valued partner in helping us stay informed on evolving U.S. state and federal data privacy & AI legislation impacting the life sciences industry. Its proactive monitoring of emerging bills, particularly those presenting heightened risk to our vertical, supports our internal prioritization and external engagement efforts. We also greatly value the practical resources PAILA offers, including template letters and proposed amendments that support engagement with state legislators. While PAILA does not provide direct lobbying support, its expertise and guidance have been incredibly useful."



Eric Berman
*Vice President, Ethics and Compliance
Officer, Chief Privacy Officer*
AbbVie



Helen Fitzpatrick
Vice President, State Government Affairs
AbbVie



**Coming
in 2026**

IPMPC Cybersecurity Program Team (CPT)

Increasingly, life sciences companies are defining new roles for legal and compliance professionals to help their businesses navigate the complex data and cybersecurity risk landscape. These professionals struggle from a core problem: cybersecurity issues lack a clear organizational home. Managing data challenges, overlap with privacy and AI functions, and a rapidly-shifting regulatory landscape has challenged companies. The IPMPC Cybersecurity Program Team (CPT) was established in December 2025 to provide an industry-specific forum to discuss best practices, conduct benchmarking, collaboratively address emerging issues, and eventually become a leading industry voice.

In 2026, the CPT will meet every 8 weeks to receive updates on global cybersecurity legal developments and engage in benchmarking discussions. Its resources and tools will be determined by CPT participants. Work product may include:

- Aggregated benchmarking surveys
- Legislation tracking
- Education via external thought leaders
- Contract templates
- Comparison of cybersecurity frameworks
- Further education on NIS2, DOJ DSP implications, and CISA final rule

"The IPMPC Cybersecurity Program Team (CPT) is uniquely positioned to help life sciences companies translate a rapidly evolving cybersecurity and regulatory landscape into practical, reusable approaches that reduce risk and improve operational readiness. By enabling cross-company collaboration and benchmarking on key issues and emerging regulatory expectations, the CPT delivers immediate, real-world value to in-house teams. As a trusted forum for sharing actionable practices and developing standardized playbooks, the CPT serves as a critical "center of gravity" for advancing cybersecurity program governance across the life sciences industry."



Jeffrey Nass
*Senior Corporate Counsel,
Global Privacy
Pfizer*



Jim Sfekas
*Associate Vice President, Assistant
General Counsel, Cybersecurity
Eli Lilly*



*New
in 2025*

2025 New & Updated Resources

IPMPC regularly develops and updates ready-to-use resources based on member priorities, including charts tracking legislative activity, charts analyzing and comparing legal requirements across frameworks, template contract language, legal analyses and executive briefing materials, and compliance checklists. Examples of new resources developed or updated for IPMPC members in 2025 include:

- ✓ Decision tree for analyzing data transactions under the DOJ Final Rule
- ✓ Template project plan for implementing the DOJ Final Rule
- ✓ Template contract terms for contracting with non-covered persons under the DOJ Final Rule
- ✓ CISA security checklist for restricted transactions under the DOJ Final Rule
- ✓ Chart tracking AI laws and guidance around the world
- ✓ Chart comparing EU AI Act to other AI governance requirements and standards
- ✓ Checklist for EU AI Act conformity assessment compliance
- ✓ Chart tracking data privacy laws around the world
- ✓ Global chart on application of privacy laws to public information
- ✓ Chart summarizing US state privacy law application thresholds and effective dates
- ✓ Chart summarizing opt-in and opt-out requirements across US state privacy laws
- ✓ Guidelines for US text message programs
- ✓ Template responses for EU DSRs and FAQs for denial of access requests



Engagement & Events

IPMPC maintains strong relationships with global life sciences stakeholders including industry associations, privacy regulators, and thought leaders. In 2025, IPMPC leveraged industry conferences to hold adjacent networking gatherings, in-person benchmarking meetings, and collaborative discussions with key stakeholders, including:

- Board of Directors meetings in Washington, D.C. and Brussels with the option for virtual participation
- Joint benchmarking sessions with the European Federation of Pharmaceutical Industries and Associations (EFPIA) and MedTech Europe in Brussels
- Networking receptions for IPMPC members and friends in Washington, D.C. and Brussels
- Presentation and Q&A on compliance with the EU AI Act with the Catalan Data Protection Authority
- Presentation and Q&A on EU-US cross-border data flows with the US Department of Commerce Office of Global Data Policy and Privacy

In 2026, in addition to networking gatherings in connection with industry conferences, IPMPC will hold:

- 2-day privacy retreats for the Board of Directors in the spring and fall, to allow more time for dedicated benchmarking and resource development around challenges facing leaders of global privacy "plus" programs
- 3 gatherings of the Asia-Pacific Roundtable and China Privacy Compliance Subteam in Shanghai for benchmarking and updates on regional developments



Member Companies

Abbott Laboratories
AbbVie
Amgen
Amicus Therapeutics
Astellas Pharma
AstraZeneca
Baxter
Becton Dickinson
BeOne Medicines
BioMarin
Boehringer-Ingelheim
Boston Scientific
Bristol Myers Squibb
Cochlear Limited
Cook Medical
Daiichi Sankyo
Edwards Lifesciences
Eli Lilly and Company
Formation Bio
Fresenius Medical Care
GE Healthcare
Genentech/Roche
Genmab
Gilead Sciences
GSK
Idorsia
Incyte
Insmed
Jazz Pharmaceuticals
Kyowa Kirin
Madrigal Pharmaceuticals
Merck Sharp & Dohme
Moderna
Novartis
Novo Nordisk
Organon & Co.
Opella
Otsuka Pharmaceutical Co.
Pfizer
Regeneron Pharmaceuticals
Sanofi
Servier Pharmaceuticals
Solventum
Stryker
Sumitomo Pharma America
Takeda Pharmaceuticals
UCB Pharma
Vantive
Vertex Pharmaceuticals

Board of Directors



Charlie Blanchard
Chair of IPMPC
Amgen



Laura Donahue
Vice Chair of IPMPC
Eli Lilly

Abbott Laboratories

Jacob Springer
Ravi Kiran

AbbVie

Eric Berman
Mita Lakhia

Amgen

Charlie Blanchard
Omid Papehn

Astellas Pharma

Theresa Niland
Antonios Roussos

AstraZeneca

Amy Papili
Tomas Dalentoft

Baxter

Efstathia Gkika
Mary Deligianni

Becton Dickinson

Luca Nevano

BeOne Medicines

João Barreiro

Boehringer-Ingelheim

Linda Mancini
Liana Newton

Boston Scientific

Ericka Snyder
Jumi Kassim

Bristol Myers Squibb

Alejandro Gené
Andrea Walker-Modu

Cook Medical

Megan Charlesworth

Daiichi Sankyo

Daniel Font
Mike Donnelly

Edwards Life Sciences

Jeffrey Dennis
Sadaf Djavadi

Eli Lilly and Company

Laura Donahue
Nick Merker

Fresenius Medical Care

Dorene Stupski
Jamie Sorley

GE HealthCare

Lara Liss

Genentech/Roche

Kimberly Gold
Florian Zabel

Gilead Sciences

Danielle Manner

GSK

Catherine Baena
Jesús Herranz

Incyte

Eirini Tsotra

Jazz Pharmaceuticals

Rachel Ralston
Jessica Vialle

Kyowa Kirin

Chad McManamy
Oana Mahan

Merck Sharp & Dohme

Melissa Fukushima
Michael Swartz

Moderna

Zoe Philippides
Marcus Sinha

Novartis

Franziska Janorschke
Teresa Patraquim da Conceição

Planning Committee

Eric Berman *AbbVie*

Antonios Roussos *Astellas*

Efstathia Gkika *Baxter*

Alejandro Gené *Bristol Myers Squibb*

Nick Merker *Eli Lilly*

Agatha O'Malley *Otsuka*

Ashley Bashore *Regeneron*

Rachel Chapman *Takeda*

Novo Nordisk

Amie Philips Pablo
Pernille Daksha Villadsen

Opella

Luca Isnardi
Simone Cammisuli

Organon and Company

Terry-Ann Cooper
Guilherme Peretti

Otsuka Pharmaceutical Company

Agatha O'Malley
David McKinney

Pfizer

Joanna Levin
Chiara Formenti-Ujlaki

Regeneron Pharmaceuticals

Patrice Ettinger
Ashley Bashore

Sanofi

Xavier Jean
Lionel de Souza

Solventum

Mohammad Amer

Stryker

Allana Nason
Melissa Van Buhler

Takeda Pharmaceuticals

Rachel Chapman
Marco Palladino

UCB

Donovan Sheppard
KB Borrelli

Vantive

Michael Standard
Sarah Leathwood

Vertex Pharmaceuticals

Sara Berkson
Michael Bullard

IPMPC Secretariat

In Support of the IPMPC, the Secretariat:

Prepares legal analyses and drafts
compliance and training tools and materials

Coordinates regular industry benchmarking

Facilitates dialogue, consensus-building, and governance


Manages outreach and legislative contacts

Organizes teleconferences, meetings, and workshops

Prepares meeting agendas, summaries, and presentations

Serves as antitrust counsel

For more information and to stay up to
date on IPMPC activities, scan or visit:



ipmpc.org



[LinkedIn](#)

The law firm of Faegre Drinker Biddle & Reath LLP serves as Legal Counsel and Secretariat to the IPMPC. Composed of attorneys, scientists, and project managers, the Consortia Management Team forms and supports life sciences industry collaborations that help companies throughout the world address complex topics of mutual interest. For more than 25 years, the team's work with these collaborations has focused on issues impacting the pharmaceutical and medical device industries.

IPMPC Membership Inquiries

Membership in the IPMPC is open to research-based medical device and pharmaceutical companies. Because membership is at the company level, members enjoy unlimited participation on IPMPC working groups and IPMPC educational webinars.

For questions about the IPMPC's priorities, progress, or membership, please email info@ipmpc.org or contact:



Mary Devlin Capizzi

mary.devlincaipizzi@faegredrinker.com
+1 202 230 5101



Maureen Donahue Hardwick

maureen.hardwick@faegredrinker.com
+1 202 230 5133



Peter A. Blenkinsop

peter.blenkinsop@faegredrinker.com
+1 202 230 5142



Reed Abrahamson

reed.abrahamson@faegredrinker.com
+1 202 230 5672



Bridget Macaulay

bridget.macaulay@faegredrinker.com
+1 202 230 5111